What is the first FDA-approved anti-sense drug for the treatment of CMV retinitis?

The first FDA-approved anti-sense drug specifically for the treatment of cytomegalovirus (CMV) retinitis is Vitravene. This medication contains the active ingredient fomivirsen, which is an anti-sense oligonucleotide designed to inhibit the replication of the CMV virus by binding to its mRNA. This mechanism prevents the virus from producing essential proteins required for its replication and thus helps in managing the condition effectively.

The significance of Vitravene lies in its targeted approach to viral infection, unique among antiviral therapies, which often rely on targeting the viral polymerase or other functions essential to viral life cycles. The development of Vitravene was crucial for immunocompromised patients, particularly those with AIDS, as CMV retinitis can lead to severe vision loss if not treated promptly.

The other options mentioned, such as Zolmitriptan, are primarily used for migraine treatment and do not have antiviral properties relevant to CMV. Ganciclovir is an antiviral medication that is effective against CMV but is not an anti-sense drug; it works by inhibiting viral DNA synthesis. Interferon is a type of cytokine used in various viral infections and has a different mechanism of action altogether